AARP (2021)

A small study has found that the experimental drug donanemab may slow cognitive decline in Alzheimer's patients. It joins others that show promise.



Comments

No comments yet. Be the first to comment!

MORE RESOURCES FROM SOURCE

More in Course Chunks from   AARP